The Latin America, Middle East and Africa Helicobacter Pylori Diagnostics Market should witness market growth of 7.7% CAGR during the forecast period (2023-2030).
Helicobacter pylori (H. pylori) is a bacteria that can stay in the digestive tract after they enter the body. These bacteria can eventually lead to ulcers, which are sores that develop on the stomach or upper small intestinal lining. Hence, the need for diagnosis is increasing to decrease the cases of patients with ulcers or gastric cancer. The key factors propelling the market growth are the development in diagnostics methods, growing infectious diseases, and the rising cases of gastric cancer, which are projected to drive market growth.
Due to the availability of many cutting-edge technologies, including enzyme immunoassays, which are utilized for the detection of antibodies, the immunoassay segment, which currently accounts for a sizeable portion of the market, is predicted to exhibit a similar pattern over the projected period. The main drivers in the immunoassay are the increased incidence of gastritis and Helicobacter pylori infections and technical developments.
In Brazil, So Paulo (25.0), Goiania (23.7), and Curitiba (21.6) had the greatest annual average incidence rates for gastric cancer, adjusted by age per 100 thousand men, for the PBCRs that were analyzed. In terms of women, Goiania (11.3), So Paulo (11.01), and Ja (9.0) had the highest age-adjusted annual average incidence rates per one hundred thousand women. Recife (11.8 for males) and Joo Pessoa (5.2 for women) were the cities with the lowest rates. According to the 2013 Saudi Arabia Cancer Incidence Report, the incidence rate for newly diagnosed cases of gastric cancer in Saudi Arabia was 2.7% in 2013. As a result, the LAMEA market is anticipated to expand due to the growing gastric cancer cases, which is expected to increase the demand for diagnostics to identify helicobacter pylori will drive the market growth.
The Brazil market dominated the LAMEA Helicobacter Pylori Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $13.1 Million by 2030. The Argentina market is estimated to grow a CAGR of 8.2% during (2023-2030). Additionally, The UAE market would experience a CAGR of 7.3% during (2023-2030).
Based on Test Type, the market is segmented into Non-invasive and Invasive. Based on End-user, the market is segmented into Diagnostics Laboratories, Hospitals, and Others. Based on Method, the market is segmented into Laboratory Based Test and Point of Care Test. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Biohit Oyj, Abbott Laboratories, Quidel Corporation, Gulf Coast Scientific, Inc. (Gulf Coast Medical Center), Meridian Bioscience, Inc. (SD Biosensor Co., Ltd.), Avanos Medical, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc. and F. Hoffmann-La Roche Ltd.
Helicobacter pylori (H. pylori) is a bacteria that can stay in the digestive tract after they enter the body. These bacteria can eventually lead to ulcers, which are sores that develop on the stomach or upper small intestinal lining. Hence, the need for diagnosis is increasing to decrease the cases of patients with ulcers or gastric cancer. The key factors propelling the market growth are the development in diagnostics methods, growing infectious diseases, and the rising cases of gastric cancer, which are projected to drive market growth.
Due to the availability of many cutting-edge technologies, including enzyme immunoassays, which are utilized for the detection of antibodies, the immunoassay segment, which currently accounts for a sizeable portion of the market, is predicted to exhibit a similar pattern over the projected period. The main drivers in the immunoassay are the increased incidence of gastritis and Helicobacter pylori infections and technical developments.
In Brazil, So Paulo (25.0), Goiania (23.7), and Curitiba (21.6) had the greatest annual average incidence rates for gastric cancer, adjusted by age per 100 thousand men, for the PBCRs that were analyzed. In terms of women, Goiania (11.3), So Paulo (11.01), and Ja (9.0) had the highest age-adjusted annual average incidence rates per one hundred thousand women. Recife (11.8 for males) and Joo Pessoa (5.2 for women) were the cities with the lowest rates. According to the 2013 Saudi Arabia Cancer Incidence Report, the incidence rate for newly diagnosed cases of gastric cancer in Saudi Arabia was 2.7% in 2013. As a result, the LAMEA market is anticipated to expand due to the growing gastric cancer cases, which is expected to increase the demand for diagnostics to identify helicobacter pylori will drive the market growth.
The Brazil market dominated the LAMEA Helicobacter Pylori Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $13.1 Million by 2030. The Argentina market is estimated to grow a CAGR of 8.2% during (2023-2030). Additionally, The UAE market would experience a CAGR of 7.3% during (2023-2030).
Based on Test Type, the market is segmented into Non-invasive and Invasive. Based on End-user, the market is segmented into Diagnostics Laboratories, Hospitals, and Others. Based on Method, the market is segmented into Laboratory Based Test and Point of Care Test. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Biohit Oyj, Abbott Laboratories, Quidel Corporation, Gulf Coast Scientific, Inc. (Gulf Coast Medical Center), Meridian Bioscience, Inc. (SD Biosensor Co., Ltd.), Avanos Medical, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc. and F. Hoffmann-La Roche Ltd.
Scope of the Study
By Test Type
- Non-invasive
- Invasive
By End-user
- Diagnostics Laboratories
- Hospitals
- Others
By Method
- Laboratory Based Test
- Point of Care Test
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Cardinal Health, Inc.
- Biohit Oyj
- Abbott Laboratories
- Quidel Corporation
- Gulf Coast Scientific, Inc. (Gulf Coast Medical Center)
- Meridian Bioscience, Inc. (SD Biosensor Co., Ltd.)
- Avanos Medical, Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- F.Hoffmann-La Roche Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Helicobacter Pylori Diagnostics Market by Test Type
Chapter 4. LAMEA Helicobacter Pylori Diagnostics Market by End User
Chapter 5. LAMEA Helicobacter Pylori Diagnostics Market by Method
Chapter 6. LAMEA Helicobacter Pylori Diagnostics Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Cardinal Health, Inc.
- Biohit Oyj
- Abbott Laboratories
- Quidel Corporation
- Gulf Coast Scientific, Inc. (Gulf Coast Medical Center)
- Meridian Bioscience, Inc. (SD Biosensor Co., Ltd.)
- Avanos Medical, Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
Methodology
LOADING...
